Developing lipid nanoparticle-based siRNA therapeutics for hepatocellular carcinoma using an integrated approach

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2308-2318

  Li, Leiming ^a   Wang, Rongqi ^a   Wilcox, Denise ^a   Sarthy, Aparna ^a   Lin, Xiaoyu ^a   Huang, Xiaoli ^a   Tian, Lu ^a   Dande, Prasad ^a   Hubbard, Robert D ^a   Hansen, Todd M ^a   Wada, Carol ^a   Zhao, Xiaobin ^a   Kohlbrenner, William M ^a   Fesik, Stephen W ^a   Shen, Yu ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID NANOPARTICLE; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC THERAPY; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84887452245     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443-53.
2. Shen Y. Advances in the development of siRNA-based therapeutics for cancer. I Drugs 2008;11:572-8.
3. Li L, Shen Y. Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Ther 2009;9:609-19.
4. Akinc A,Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26:561-9.
5. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, et al. Atu027, a liposomal small interfering RNAformulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008;68:9788-98.
6. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92.
7. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-4.
8. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, et al. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 2007;104:12982-7.
9. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009;119:661-73.
10. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28:172-6.
11. Lin X, Li L, Wang R, Wilcox D, Zhao X, Song J, et al. A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. Rna 2011;17:603-12.
12. Wheeler JJ, Palmer L, Ossanlou M, MacLachlan I, Graham RW, Zhang YP, et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther 1999;6:271-81.
13. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology (Baltimore, MD) 2005;41:1349-56.
14. Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 2005;107:276-87.
15. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006;13:328-37.
16. Dande PA, Hansen TM, Hubbard RD, Sarthy AV, Shen Y, Tian L, et al., inventors; Abbott Laboratories, assignee. Cationic lipids and uses thereof. United States patent US 20100104629. 2010 Apr 29.
17. Zhao X, Liu Y, Song J, Yong H, Li L, Shen Y, et al. Cationic lipids percentage and processing temperature are critical in designing siRNA lipid nanoparticles. J Drug Target 2012;20: 281-9.
18. Li L, Wang R, Wilcox D, Zhao X, Song J, Lin X, et al. Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther 2012;19:775-80.
19. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 2001;1513:193-206.
20. MacLachlan I, Cullis P. "Diffusible-PEG-lipid stabilized plasmid lipid particles." Adv Genet 2005;53:157-88.
21. Silvius JR, Zuckermann MJ. Interbilayer transfer of phospholipidanchored macromolecules via monomer diffusion. Biochemistry 1993;32